Integrating this platform with the National Standard for anti-SARS-CoV-2 mucosal IgA (No. 300052-202401, 1000 U/mL) provides a reliable and scalable framework for evaluating mucosal vaccines, setting a precedent for standardizing mucosal antibody assays for other infectious diseases. Here, CD79A is linked to infectious disease.